Luciferase-expressing Tumor Cells
Luciferase-expressing Tumor Cells - Related Videos
08:09
High-throughput Titration of Luciferase-expressing Recombinant Viruses
0 Views •
Cited by 14 •
2014
This article presents a high-throughput luciferase expression-based method of titrating various RNA and DNA viruses using automated and manual liquid handlers.
10:38
Monitoring Cell-autonomous Circadian Clock Rhythms of Gene Expression Using Luciferase Bioluminescence Reporters
0 Views •
Cited by 78 •
2012
Circadian clocks function within individual cells, i.e., they are cell-autonomous. Here, we describe methods for generating cell-autonomous clock models using non-invasive, luciferase-based real-time bioluminescence technology. Reporter cells provide tractable, functional model systems for studying circadian biology.
03:23
Measurement of the In Vivo Burden of Bacteria Expressing Luciferase in an Insect Larva
0 Views •
2025
This video showcases the in vivo bacterial burden measurement using Bacillus Calmette-Guérin, BCG, lux-infected insect larvae. The process involves larval homogenization, treatment with a luciferase substrate, and bioluminescence measurement to determine relative light units that correlate with bacterial burden.
07:10
Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
0 Views •
Cited by 17 •
2011
A method for reliably grafting luciferase-tagged human malignant peripheral nerve sheath tumor cells into the sciatic nerve of immunodeficient mice is described. The use of bioluminescence imaging to demonstrate proper establishment of tumor grafts and criteria for random segregation of animals into study groups are also discussed.
03:19
Transduction to Label PDX Tumor Cells: Introducing Lentivirus Expressing Fluorescent Marker into the Tumor Cell In Vitro
0 Views •
2023
The following video describes a technique of transduction to label (patient-derived xenografts) PDX tumor cells, which is used for introducing lentivirus expressing green-fluorescent protein and luciferase reporters into the tumor cell in vitro.
FAQs
The luciferase reaction requires a compatible substrate, so substrate choice and availability directly determine whether labeled cells produce a measurable signal. Once supplied, the enzyme catalyzes light production, and an imaging system detects the emitted bioluminescence. This dependence makes substrate administration an essential experimental condition when comparing tumor signals across animals or time points.
The measured signal reflects viable labeled-cell numbers under defined conditions, rather than an unrestricted record of every cell previously present. Consequently, a declining signal can indicate reduced viable tumor-cell burden, while any change must be interpreted with the relevant substrate and imaging conditions in mind. This distinction supports evaluation of tumor progression and treatment effects.
Comparisons are most meaningful when researchers maintain defined conditions for substrate administration and imaging. The substrate must be compatible with the luciferase produced by the cells, and the emitted light must be captured with a sensitive imaging system. Keeping these factors consistent helps relate differences in signal to changes in viable labeled-cell numbers rather than to measurement conditions.
These cells allow investigators to follow tumor behavior while examining immune-cell activity or pathogen-associated effects in living models. Repeated measurements can show how the tumor signal changes during disease progression or experimental intervention, helping connect alterations in tumor burden with immunological responses and infection-related influences without relying only on separate endpoint observations.
The workflow begins with administration of the labeled tumor cells, followed at selected times by a compatible substrate. Luciferase then catalyzes the light-producing reaction, and a sensitive imaging system records the emitted bioluminescence. Researchers compare the resulting signal across time to assess tumor growth, distribution, or changes associated with treatment and disease conditions.
Longitudinal imaging is useful when researchers need to monitor the same tumor repeatedly during progression or treatment. Tracking one tumor over time reveals changing bioluminescent signal in relation to viable labeled-cell numbers, treatment response, or pathogen-associated effects. It can also reduce sampling requirements and provide a time-resolved view of outcomes in living models.